Long-term Efficacy, Visual Performance and Patient Reported Outcomes With a Trifocal Intraocular Lens: Six-year Follow-up

Qvision, Ophthalmology Department1 site in 1 country37 target enrollmentSeptember 15, 2020

ConditionsCataract

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Cataract
Sponsor: Qvision, Ophthalmology Department
Enrollment: 37
Locations: 1
Primary Endpoint: Monocular visual acuity
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The main aims of this study were to evaluate the patient reported outcomes (PROs), safety and efficacy, after 6-year (66 - 78 months) from the binocular implantation of the AT LISA tri 839MP. A secondary aim was to evaluate new metrics such as contrast sensitivity defocus curves and light distortion analysis.

Detailed Description

Retrospective cross-sectional study with two stages: • Phone call interview: First stage included patient reported outcomes of visual function, spectacle independence and satisfaction through questionnaires conducted by a phone call in all the patients implanted in our center with AT LISA 839MP from March 2014 to June 2015 (n=92) which accomplished inclusion / exclusion criteria and were able to be contacted by phone (n=62). The incidence of Nd-YAG capsulotomy was retrospectively evaluated through the revision of the medical history, in patients for which capsulotomy was conducted in our center, or a question, for those treated in another center. • Study visit: Second stage included the consecutive invitation of these phone interviewed patients to a visit in our center for a long-term visual performance assessment up to accomplish the required sample size (n=37). Corrected and uncorrected monocular visual acuities were the primary end-points for testing non-inferiority hypothesis in comparison to 12-month follow-up mean results reported in the literature. Secondary variables of assessment were contrast sensitivity defocus curve and light distortion analysis.

Registry

clinicaltrials.gov

Start Date

September 15, 2020

End Date

November 24, 2020

Last Updated

5 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Qvision, Ophthalmology Department

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Phone call interview:
•Patients of either sex, 45 years of age or older at the time of surgery and less than 80 years of age at the time of the phone call.
•Patients implanted bilaterally with the AT LISA 839MP MIOL in the capsular bag.
•No surgical complications reported in the clinical history that could affect postoperative visual acuity: damage to the capsular bag, intraocular hemorrhage, etc.
•Operated between 66 months from the first implanted eye and up to 78 months from the surgery of the second eye
•Patient able to hear, understand and give express consent orally.
•Study visit:
•To have participated in the first stage of the study corresponding to the phone call interview.
•Irregular astigmatism in either eye measured with corneal tomography (total high-order corneal aberrations at 4 mm \< 0.5 μm).
•Patient able to read, understand and provide a written informed consent form.

Exclusion Criteria

•Phone call interview:
•Any eye disease documented in the patient's clinical history that may potentially cause a loss of visual acuity or diplopia: Active or recurrent pathology of the anterior segment (chronic uveitis, iritis, iridocyclitis, rubeosis iridis, uncontrolled glaucoma, etc.), retinal or optic nerve pathologies such as diabetic retinopathy, macular degeneration, etc.
•Eye surgery (including laser refractive surgery) performed before or after the operation with the intraocular lens.
•Study Visit:
•PCO ≥ 2 according to surgeon criteria that produces a loss of CDVA ≥ 0.2 logMAR
•Any eye disorder that can potentially cause a loss of visual acuity or diplopia: Active or recurrent pathology of the anterior segment (chronic uveitis, iritis, iridocyclitis, rubeosis iridis, uncontrolled glaucoma, etc.), retinal or optic nerve pathologies such as diabetic retinopathy, macular degeneration, etc.
•Eye surgery (including laser refractive surgery) performed before or after the operation with the intraocular lens.
•Use of systemic or ocular medications that may affect vision in the last 6 months.
•Subjects who participate in any clinical trial or research with drugs or medical devices within 30 days prior to entry into this research and/or during the period of participation in this research.